DNA Genotek’s OMNIgene® GUT Kit is Proposed as Standardized Test for Worldwide Studies of the Human Microbiome
August 29 2016 - 6:00AM
OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that a
study conducted by Human Longevity, Inc. (HLI) and published in the
Journal Scientific Reports (Nature Publishing Group) on August 25,
2016 proposes the use of the OMNIgene•GUT microbiome sample
collection and stabilization device sold by OraSure’s wholly-owned
subsidiary, DNA Genotek Inc., in global microbiome studies.
The published report can be found online at
http://www.nature.com/articles/srep31731.
Research into the human microbiome is emerging as highly
informative to our overall understanding of health and disease
risk. The article discusses the need for standardization of
sample collection and stabilization to ensure accurate downstream
results in microbiome studies and compares OMNIgene•GUT to existing
accepted methods including use of both fresh and frozen
samples.
The HLI authors state: “Stabilization of biological samples is
crucial for accurate analysis of microbiome data, and for
comparison across studies.” They then conclude: “This stabilization
and collection device (OMNIgene•GUT) allows for ambient temperature
storage, automation, and ease of shipping/transfer of samples. The
device permitted the same data reproducibility as with frozen
samples, and yielded higher recovery of nucleic acids. Collection
and stabilization of stool microbiome samples with the DNA Genotek
collection device, combined with our extraction and WGS (whole
genome sequencing), provides a robust, reproducible workflow that
enables standardized global collection, storage, and analysis of
stool for microbiome studies.”
"DNA Genotek is pleased to provide a broad spectrum of kits for
nucleic acid collection and stabilization from multiple sample
types to enable HLI’s extensive research into genomics and
metagenomics,” said Brian Smith, Senior Vice President and General
Manager, at DNA Genotek Inc. “We are also proud to offer HLI
end-to-end logistics support through our custom kitting and
fulfillment services. HLI is a thought leader in the field and we
are honored that they have provided such positive feedback,
supporting the use of our product in support of discoveries
impacting global health and wellness.”
OMNIgene•GUT is an all in one system for the easy
self-collection and stabilization of microbial DNA from feces/stool
for gut microbiome profiling. The device allows for ambient
temperature storage and transportation and provides a liquid sample
to enable high throughput automation in a laboratory, offering
reduced costs and increased consistency and standardization.
OMNIgene•GUT OMR-200 is available for sale in the USA, and is
intended for research use only, not for use in diagnostic
procedures. This product has not been approved or cleared by the
U.S. Food and Drug Administration. OMNIgene•GUT OM-200 is
available for sale outside the U.S. and is CE marked for in vitro
diagnostic use.
About DNA Genotek
DNA Genotek Inc., a subsidiary of OraSure Technologies, Inc.
(NASDAQ: OSUR), focuses on providing high-quality biological sample
collection products and end-to-end services for human genomics,
microbiome and infectious disease applications. The Company's
Oragene•Dx and ORAcollect•Dx product lines are the first and only
FDA 510(k) cleared saliva-based DNA collection devices for in vitro
diagnostic use. DNA Genotek also offers Research Use Only products
to collect and preserve large amounts of DNA or RNA from multiple
sample types. DNA Genotek markets its products worldwide and has a
global customer base with thousands of customers in over 100
countries. For more information about DNA Genotek, visit
www.dnagenotek.com.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture
and distribution of point of care diagnostic and collection devices
and other technologies designed to detect or diagnose critical
medical conditions. Its first-to-market, innovative products
include rapid tests for the detection of antibodies to HIV and HCV
on the OraQuick® platform, oral fluid sample collection,
stabilization and preparation products for molecular diagnostic
applications, and oral fluid laboratory tests for detecting various
drugs of abuse. OraSure's portfolio of products is sold globally to
various clinical laboratories, hospitals, clinics, community-based
organizations and other public health organizations, research and
academic institutions, distributors, government agencies,
physicians' offices, commercial and industrial entities and
consumers. The Company's products enable healthcare providers to
deliver critical information to patients, empowering them to make
decisions to improve and protect their health. For more
information on OraSure Technologies, please visit
www.orasure.com.
Ronald H. Spair
Chief Financial Officer
610-882-1820
Investorinfo@orasure.com
Ron Ticho
SVP, Corporate Communications
484-353-1575
media@orasure.com
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Apr 2023 to Apr 2024